Free tool
FAERS Monitor: Hercessi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761346 or its brand name (Hercessi, Trastuzumab-Strf). Reports on generic versions are filed under their own applications.
Reports
14
Serious
12
86% of reports
Hospitalization
6
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea7
- nausea4
- vomiting4
- enterocolitis3
- leukopenia3
- neutropenia3
- thrombocytopenia3
- alopecia2
- anaemia2
- asthenia2
- back pain2
- drug eruption2
- fatigue2
- headache2
- hepatic function abnormal2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 3 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,145 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| enterocolitisSignal | 3 | 781.1 | 286.4 | 1,622 |
| drug eruption | 2 | 169.6 | 47.0 | 188 |
| leukopeniaSignal | 3 | 90.1 | 33.0 | 183 |
| hepatic function abnormal | 2 | 80.5 | 22.3 | 88 |
| thrombocytopeniaSignal | 3 | 40.3 | 14.8 | 79 |
| neutropeniaSignal | 3 | 33.1 | 12.2 | 65 |
| diarrhoeaSignal | 7 | 16.3 | 9.6 | 88 |
| anaemia | 2 | 15.8 | 4.4 | 15 |
| alopecia | 2 | 15.3 | 4.2 | 14 |
| back pain | 2 | 12.9 | 3.6 | 12 |
| vomitingSignal | 4 | 12.8 | 5.6 | 33 |
| asthenia | 2 | 8.0 | 2.2 | 6 |
| nauseaSignal | 4 | 7.6 | 3.3 | 17 |
| headache | 2 | 4.8 | 1.3 | 3 |
| fatigue | 2 | 3.9 | 1.1 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.